Article Information
History
- September 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Janna Krueger1,2,
- Francois Santinon1,2,
- Alexandra Kazanova1,2,
- Mark Issa1,2,
- Bruno Larrivee3,
- Catalin Milhalcioiu4 and
- Christopher E. Rudd1,2,5
- 1Division of Immuno-Oncology, Research Center Maisonneuve-Rosemont Hospital (CR-HMR) Montreal, Quebec H1T 2M4
- 2Department of Microbiology, Infection and Immunology, Universite de Montreal, Montreal, Quebec, Canada
- 3Ophthalmology, Universite de Montreal, Montreal, Quebec, Canada
- 4Division of Medical Oncology, Department of Medicine, McGill University Health Center, Canada
- ↵5To whom correspondence should be addressed- Christopher E. Rudd; christopher.e.rudd{at}umontreal.ca
Posted September 30, 2020.
Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy
